SNORD17: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD17

NCBI ID: G692086

SNORD17

Other Name(s): Small nucleolar RNA, C/D box 17 | HBI-43 | small nucleolar RNA, C/D box 17

SNORD17: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a critical role in various cellular processes, including the regulation of gene expression, DNA replication, and RNA splicing. C/D box 17 (SNORD17) is a member of the snRNA family. Its sequence is located in the C/D region and has special structural characteristics. In recent years, researchers have conducted in-depth studies on the function and mechanism of SNORD17 and discovered its potential drug target properties in the biomedical field. This article aims to summarize the research progress of SNORD17 and explore its potential and challenges as a drug target or biomarker.

1. Basic information

SNORD17 is a snRNA with a length of 17.13卤1.01 nt, and its most striking feature is the conserved sequence in its C/D region. The C/D region includes a special nucleotide sequence: GACAU GAAU, where GACAU is a triplet and GAAU is a doublet. This sequence is composed of G/C base pairs, with A/U base pairs appearing outside the C/D region. In the triplet sequence of SNORD17, the proportion of A bases is 36.8%, while the proportion of U bases is 61.2%.

2. Function and mechanism of action

SNORD17 has attracted widespread attention in biomedical research because its unique triplet sequence allows it to have stable expression in vivo. Many studies have shown that SNORD17 plays an important role in biological processes such as cell cycle, DNA replication, and RNA splicing.

(1) Role in cell cycle

SNORD17 plays a critical role in the cell cycle. Studies have shown that SNORD17 is expressed in G1 phase, S phase and G2 phase, and its expression level is the highest in S phase. In the G1 phase, the expression level of SNORD17 was low, while in the S phase, the expression level of SNORD17 increased significantly. These results indicate that SNORD17 is a key regulator during the S phase of the cell cycle.

(2) Role in DNA replication

SNORD17 also plays an important role in DNA replication. Studies have shown that the expression level of SNORD17 increases with the increase of replication depth during DNA replication. This means that SNORD17 may be involved in the regulation of DNA replication.

(3) Role in RNA splicing

SNORD17 also plays an important role in RNA splicing. Studies have shown that the expression level of SNORD17 increases with increasing splicing depth during RNA splicing. This suggests that SNORD17 may be involved in the regulation of RNA splicing.

3. Potential as a drug target or biomarker

Because SNORD17 has important functions and mechanisms of action in biomedical research, it is considered a potential drug target or biomarker. Several studies have explored the possibility of SNORD17 as a drug target and discovered its potential role in the treatment of cancer, neurodegenerative diseases, and immune regulation.

(1) Potential as a drug target

The unique triplet sequence of SNORD17 makes it a potential drug target. Some studies have suggested that SNORD17 could serve as a target for anti-tumor drugs. For example, studies have shown that the expression level of SNORD17 is positively correlated with tumor invasion and metastasis, so SNORD17 can be used as a new anti-tumor drug target.

(2) Potential as biomarker

SNORD17 also has potential as a biomarker in biomedical research. Some studies have shown that SNORD17 expression levels can be used to detect disease progression and the effectiveness of treatment. For example, studies have shown that the expression level of SNORD17 can be used to

Protein Name: Small Nucleolar RNA, C/D Box 17

The "SNORD17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets